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Abstract
Purpose—Flavopiridol is primarily a cyclin-dependent kinase (CDK)-9 inhibitor and we
performed a dose escalation trial to determine the maximum tolerated dose, safety, and generate a
pharmacokinetic profile.
Methods—Patients with a diagnosis of relapsed myeloma after at least two prior treatments were
included. Flavopiridol was administered as a bolus then continuous infusion weekly for 4 weeks in
a 6 week cycle.
Results—Fifteen patients were treated at three dose levels (30 mg/m2 bolus, 30 mg/m2 CIV to 50
mg/m2 bolus, 50 mg/m2 CIV). Cytopenias were significant and elevated transaminases (grade 4 in
3 patients, grade 3 in 4 patients, and grade 2 in 3 patients) were noted but were transient. Diarrhea
(grade 3 in 6 patients, grade 2 in 5 patients) did not lead to hospital admission. There were no
confirmed partial responses although one patient with t(4;14) had a decrease in his monoclonal
protein greater than 50% percent that did not persist. Pharmacokinetic properties were similar to
prior publications and immunohistochemical staining for cyclin D1 and phospho-retinoblastoma
did not predict response.
Conclusions—Flavopiridol as a single agent given by bolus then infusion caused significant
diarrhea, cytopenias, and transaminase elevation but only achieved marginal responses in relapsed
myeloma (ClinicalTrials.gov identifier NCT00112723).
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INTRODUCTION
Multiple Myeloma (MM) is a plasma cell neoplasm for which modern therapies have
approximately doubled overall survival[17], primarily due to bortezomib, a proteasome
inhibitor, and immune modulators (IMiDs) thalidomide and lenalidomide [31] that lead to
interferon regulatory factor-4 inhibition[18] and caspase-mediated apoptosis. The vast
majority of myeloma patients will still die of progressive disease leading to a search for
novel agents.
Cyclin-dependent kinase (CDK) inhibition is an attractive target as MM cells are dependent
on cell cycle dysregulation to overcome c-Myc induced apoptosis[26, 28]. Cell cycling is
regulated in part by CDK complexes, and therapeutic intervention to prevent their binding to
cyclins is of interest in myeloma as most myeloma cells have high levels of cyclin D1, D2
and/or D3[1] that phosphorylate retinoblastoma (Rb), moving cell cycle progression
forward. In vitro studies have shown marked decrease in myeloid cell leukemia-1 (MCL-1)
and phospho- RNA polymerase II after sustained exposure to Flavopiridol in U266[10],
8226[25], and OPM- 2[13] cell lines, but this could be overcome by overexpression of BCL-
XL and BCL-2 and a resistance mechanism was suggested by late MCL-1 overexpression.
Flavopiridol targets the cyclin-dependent kinase (CDK) 9/cyclin T complex (preventing
activation of RNA polymerase II)[5, 9], downregulates MCL-1[13], induces mitochondrial
permeability changes[15], and interrupts NF-κB pathway by inhibiting IκK[29]. It is highly
protein bound when in human serum, requiring a 30-minute intravenous bolus followed by
4-hour intravenous infusion – with this hybrid infusional schedule, significant responses
have been observed in patients with refractory chronic lymphocytic leukemia[3].
Previous trials using dosing based on in vitro cytotoxicity were ineffective in patients with
treated multiple myeloma[10] thought to be from inadequate AUC levels reached. We
designed a phase I dose escalation study to establish the maximum tolerated dose (MTD)
and describe toxicities associated with single agent flavopiridol in patients with relapsed
myeloma.
Methods
Clinical trial
This study was approved by the Ohio State University Cancer Institutional Review Board
and informed consent was obtained from all enrolled patients. Adult patients were required
to have symptomatic myeloma using criteria from the International Myeloma Working
Group[11] and be seen as outpatients in the myeloma clinic at The Ohio State University
Arthur G. James Hospital and Solove Research Institute. This trial was registered on
clinicaltrials.gov as NCT00112723.
Patients with a diagnosis of relapsed myeloma after at least two prior treatments with no
limit on prior therapies were included. Adequate organ function was required with creatinine
less than or equal to 1.5 mg/dL and total bilirubin less than or equal to twice the institutional
upper limit of normal. Adequate hematologic parameters were also required with a
hemoglobin greater than or equal to 9 g/dL, absolute neutrophil counter greater than or equal
to 1500/µL, and platelets greater than or equal to 50,000/µL; however, lower platelet values
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were allowed if attributable to the patient’s underlying myeloma on screening bone marrow
biopsy. Flavopiridol was administered weekly via central venous catheter as a 30 minute
intravenous bolus followed by a 4-hour continuous intravenous infusion (CIV) for 4 weeks
in a 6 week cycle. Responses were recorded based on International Myeloma Working
Group Criteria[12].
Toxicity was assessed using the Common Terminology Criteria for Adverse Events
(CTCAE), version 3.0. until July 31, 2010 and version 4.0 beginning August 1, 2010. Dose
limiting toxicity (DLT) was defined as 1) any grade 3–4 non-hematologic toxicity (except
leukopenia or neutropenia) that does not resolve or decrease to grade 1–2 within 2 weeks, or
2) any grade 4 hematologic toxicity that causes more than a one week delay in
administration of therapy. Granulocyte colony stimulating factor (G-CSF) was used at the
discretion of the treating investigator. The MTD was defined as that dose level beneath the
dose at which 2 or more of 6 patients experienced DLT.
Pharmacokinetic (PK) analysis
Plasma samples were obtained on days 1 and 22 of the first cycle. Sodium heparinized blood
was obtained at the following time points: prior to dosing (t=0), at 0.5, 1, 3, 4.5, 6, 8 and 24
hours after initiation of infusion on day 1 and day 22. Blood samples were centrifuged, and
plasma was stored at (−70)°C until analysis. Flavopiridol quantification in plasma samples
was achieved using a validated liquid chromatography-tandem mass spectrometry assay as
previously described[23]. Plasma flavopiridol concentration-time data were analyzed using
standard non-compartmental methods in WinNonlin Professional v 5.2.1 (Pharsight,
Mountain View, CA).
Immunohistochemical analysis
We hypothesized that cyclin D1 overexpression would sensitize myeloma cells to
flavopiridol[8]. Immunohistochemical staining (IHC) for Cyclin D1 (BCL-1) (Neomarkers)
and Retinoblastoma (RB-358, Leica), and phospho-RB (pRB, Leica) was performed on the 4
micron (µm) sections of formalin-fixed, paraffin-embedded (FFPE) bone marrow biopsy or
clot sections. Briefly, sections were placed in a 60°C oven for one hour, cooled, and
deparaffinized and rehydrated through xylenes and graded ethanol solutions to water. All
slides were quenched for 5 minutes in 3% hydrogen peroxide (v/v) for endogenous
peroxidase. Antigen retrieval was performed by a heat method in which the specimens were
placed in a citric acid solution (pH 6.1) for 25 minutes at 94°C and cooled for 15 minutes.
Slides were then placed on an autostainer (Dako Immunostaining) for
immunohistochemistry. The antibodies for Cyclin D1, RB, and pRB were used at a dilution
of 1:100, 1:50, and 1:100, respectively and incubated for 30 minutes at room temperature.
The Envision Plus horseradish peroxidase (HRP) with 3,3'-diaminobenzidine (DAB)
chromogen (Dako) was used to produce a brown precipitate. Slides were then counterstained
in Richard Allen hematoxylin. A scoring system was developed from a single observer
(author WZ) based on intensity for the majority of the stained plasma cells with 0–1
negative, 2 as moderate, and 3 strong.
Statistical analysis
This protocol is a standard 3×3 phase I dose escalation study of single agent flavopiridol to
determine the maximum tolerable dose of the agent to be used in a phase II evaluation of
response. Separate, parallel phase I studies were conducted in each of six disease groups
(indolent B-cell NHL, mantle cell lymphoma, intermediate grade B-cell NHL, T/NK-cell
NHL, Hodgkin’s lymphoma, multiple myeloma) in order to determine disease-specific DLT,
MTD and recommended phase II doses.
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Spearman correlation analysis (two-tailed p-values) was performed between clinical
response and immunohistochemical staining results for BCL-1, RB, and pRB using Prism v
5.0F (GraphPad Software, San Diego, CA).
Statistical analyses for PK parameters were performed on all enrolled patients with
evaluable PK data (n=15); PK profiles that yielded ≥ 30% estimated area under the
concentration versus time curve from zero to infinity (AUC(0-∞)) extrapolation were omitted
from final analyses. Paired t-tests were used to evaluate differences in AUC(0-∞) and Cmax
between days 1 and 22 of cycle 1. The associations between PK parameter estimates and
dose level were tested using one-way analysis of variance (ANOVA) and 2-sample t-tests or
nonparametric tests when appropriate. Data are described with means ± standard deviations
and/or medians with ranges. These data were analyzed using SigmaPlot v11 (Systat
Software Inc.).
Results
Patients
Fifteen patients (ages 49–81 years) with relapsed myeloma were treated. The median
number of prior therapies was 7 (3–12). At the time of study entry, 10 patients displayed a
complex karyotype, 2 patients demonstrated 17p deletion by CD138-selected fluorescence in
situ hybridization (FISH; Rosette Sep), and one patient showed t(4;14) fusion by FISH.
There were 3 patients with karyotypic chromosome 13 deletion and 9 patients with deleted
LAMP or D13S319 probes by FISH. At study entry, 8 patients had International Staging
System (ISS) stage 3 disease, 3 with stage 2, and 4 with stage 1 disease. Five patients were
treated in cohort 1 (30 mg/m2 bolus, 30 mg/m2 CIV; 30/30), 3 patients in cohort 2 (30 mg/
m2 bolus, 50 mg/m2 CIV; 30/50), and 7 patients in cohort 3 (50 mg/m2 bolus, 50 mg/m2
CIV; 50/50). The median number of cycles received was one. Two patients at the 30/30
level and one patient at 50/50 had to be replaced as they did not finish the first cycle.
Response
Immunoglobulins, free light chains, and 24-hour urine samples were obtained at screening
and then the appropriate myeloma proteins were obtained on the first day of each subsequent
cycle to follow response. There were no confirmed partial responses although one patient
had a decrease in his monoclonal protein greater than 50% percent which was not quite
maintained with the second cycle and hence qualifies as a confirmed MR. Overall there was
one minor response, one patient with stable disease for three cycles, and the remainder
suffered either progressive disease after the first cycle (4 patients) or did not continue on
study treatment (9 patients).
The one patient with a minor response had an IgA myeloma with a t(4;14), deletion
chromosome 13, and tetraploid cytogenetics by FISH that had been treated with vincristine,
doxorubicin, and high dose dexamethasone (VAD) with progression, complete response
with salvage bortezomib and dexamethasone, then an autologous transplant from which he
remained in a remission off maintenance therapy for three years until relapse then treatment
on this clinical protocol.
Toxicities
Grade 3/4 toxicities were significant (table 2). Cytopenias were considerable with grade 4
neutropenia (11 patients), grade 4 anemia (7 patients), and grade 4 thrombocytopenia (3
patients). Elevated transaminases (grade 4 in 3 patients, grade 3 in 4 patients, and grade 2 in
3 patients) were frequent but was asymptomatic and resolved in the periods between
flavopiridol exposure. Diarrhea (grade 3 in 6 patients, grade 2 in 5 patients) was common
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but did not lead to hospitalization. There were two patients with neutropenic pneumonia and
one patient with neutropenic fever.
There were eight serious adverse events related primarily to pancytopenia with or without
infection, asymptomatic elevated transaminases, or progressive myeloma. Patient E (30/50)
became febrile with grade 3 neutropenia after her initial infusion for which 20 mg
intravenous dexamethasone was added to subsequent treatments. However, on day 20 of
cycle 1, she presented septic due to citrobacter bacteremia. Patient B (30/50) became
infected day 2 of cycle 1 with pseudomonas bacteremia, and patient P (50/50) became
pancytopenic and septic during cycle 1. Patients K (50/50) and J (30/50) both developed
asymptomatic grade 4 elevated transaminases. On day 1 of cycle 2, Patient C (30/50)
developed mental status changes from hypercalcemia attributed to progressive disease.
Patient G (30/50) developed grade 4 neutropenia and thrombocytopenia with cycle 1, and
suffered a pathologic fracture just prior to treatment on cycle 2 day 1 consistent with
progressive disease. After progressing on therapy and receiving infusional DCEP
(Dexamethasone-Cyclophosphamide-Etoposide-Platinum), patient R (50/50) became septic
with grade 4 neutropenia and died within 30 days of his last dose of flavopiridol.
Immunohistochemistry
Pretreatment biopsy or aspirate samples were stained for BCL-1 (Cyclin D1, CCND1), RB,
and pRB (table 3). A single reviewer scored the intensity of staining in plasma cells. RB
staining was seen in all but one specimen. The intensity of BCL-1 and RB staining could not
be statistically associated with response (p=0.84 and p=0.12 respectively), but intense
staining was seen in two of the patients with stable disease. The staining intensity of pRB
showed no correlation with response to flavopiridol (p=0.88).
Pharmacokinetics
Plasma samples from 15 patients (a total of 24 concentration-time profiles with 187 plasma
concentration observations) were available for analysis. Three PK profiles for 3 patients
were omitted due to ≥ 30% AUC(0-∞) extrapolation, resulting in 14 plasma flavopiridol
concentration-time profiles on day 1 and 7 profiles on day 22 (Figure 2). Data points for
determining the terminal elimination phase (λz) were selected automatically in WinNonlin
and resulting λz ranges were determined to be adequate by manual review. Three dose
levels, ranging from total dose (bolus + maintenance) of 60 to 100 mg/m2, were
administered in this study. Among those with PK data on both days 1 and 22 (n=6), the
mean differences in AUC(0-∞) and Cmax for day 22 versus day 1 were not significant
(P=0.53 and P=0.57, respectively), where the average difference in AUC(0-∞) was 1.00
hr*µM, (95% CI −2.78 to 4.78 hr*µM) and the average difference in Cmax was 0.153 µM
(95% CI: −0.50 to 0.80 µM). There was no statistically significant difference between the
apparent volume of distribution based on terminal phase (Vz), total body clearance (CL) and
terminal phase elimination half-life (T1/2) for the 2 dosing days in these same individuals.
PK parameter data from cycle 1 days 1 and 22 combined are summarized in Table 4.
When the PK parameter estimates for cycle 1 day 1 were compared between the 3 dose
levels, a significantly higher mean AUC(0-∞) was observed for dose level 3 compared to
dose level 2 (P<0.05; Figure 3a). The mean AUC(0-∞) for dose level 2 was unexpectedly
lower than that of dose level 1, likely because there were only 3 concentration profiles
available for evaluation for this dose level. The mean AUC(0-∞) for dose level 3 was higher
when compared to dose level 1 but not statistically significant. The differences in mean
Cmax of all dose levels were insignificant (Figure 3b). The mean Tmax was longer in the
30/50 and 50/50 mg/m2 dose level groups compared to 30/30 mg/m2 (1.18±1.22; 1.40±1.67
hr and 0.52±0.03, respectively). However, it should be noted that there was one outlier in the
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30/50 mg/m2 dose level group (3.0 hr), and 2 outliers (4.6 and 4.5 hr) in the latter group.
The medians Tmax were comparable among the 3 dose levels.
There were also no large differences in Vz, and T1/2 of flavopiridol among the three dose
levels. The clearance parameters estimated here, except for the 30/50 mg/m2 dose level,
were very comparable to the previously published data[2]. Based on a two compartment
population pharmacokinetic model with first-order elimination, we previously reported
flavopiridol clearance of 31.4 ± 5.4 L/Hr[22]. In this study, the mean CL for the 30/30 and
50/50 mg/m2 dose levels were 39.97±20.87 and 38.56 ± 14.26 L/Hr, respectively. The CL
estimated from the 30/50 mg/m2 group was significantly higher than the other 2 groups
(p<0.005). This is consistent with the lower mean AUC estimated as presented above, and
this unexpected result should be interpreted cautiously and may be attributed to the small
sample size. Overall, pharmacokinetics appear comparable to that reported for flavopiridol
in other hematologic malignancies[2, 3, 22].
Discussion
In this phase I trial of flavopiridol in relapsed multiple myeloma, we determined the MTD at
50 mg/m2 30-minute bolus followed by 50 mg/m2 4-hour CIV. With only one documented
marginal response, we did not feel that there was adequate single agent activity to continue
into the phase II portion of the trial.
CDK inhibition is a tempting therapeutic target because increased expression of at least one
of the three CCND genes is a near universal event in plasma cell dyscrasias[1]; CCND1 is
expressed in hyperdiploid myeloma, while CCND2 is expressed by most of the remaining
tumors. D-type cyclins are critical regulators of the cell cycle that act in a complex with
cyclin-dependent kinases (CDKs) -4 or -6 to promote the phosphorylation of the
retinoblastoma protein (Rb) to initiate cellular transition from G1 to S phase[6, 7, 20, 27].
Focal amplification of cyclin D1 may be required for CDK inhibitors to keep p21CIP1 level
low and inactivate NF-κB[16], while RB1 mutations or deletions may lead to resistance to
Flavopiridol as with other CDK inhibitors, or perhaps resistance could be mediated by
autophagy as it is in CLL[19]. Notably in our trial immunohistochemical staining for BCL-1
and pRB was unable to demonstrate a correlation between the staining and response – this
staining was exploratory as a phosphorylated antibody in bone marrow samples has not been
validated and immunohistochemical analysis is semi-quantitative at best. In a phase Ib study
of Flavopiridol in combination with bortezomib[14], responses were seen in bortezomib
naïve myeloma patients, confirming the molecular studies[21] demonstrating that resistance
for bortezomib and CDK inhibitors overlap.
Flavopiridol led to considerable adverse events in this patient population and responses were
generally short-lived. It is possible that the higher doses used in this patient population in the
final cohort represent responses that we would see more commonly at even higher doses, but
unfortunately off target effects of neutropenia and diarrhea would prevent further dose
escalation. Flavopiridol is no longer being pursued in lymphoproliferative diseases but
ongoing trials are accruing in combination in myeloid neoplasms in combination with
standard cytotoxic agents. Preclinical evaluation of the CDK inhibitor AT7519 has
demonstrated the importance of glycogen synthase kinase-3β for apoptosis[24], testing that
has not been performed with most other CDK inhibitors including flavopiridol. The precise
anti-neoplastic mechanism of action of CDK inhibitors in myeloma remains controversial.
In summary this phase I trial established the MTD of single agent flavopiridol MTD to be 50
mg/m2 30-minute bolus followed by 50 mg/m2 4-hour CIV. The clinical evaluation of CDK
inhibitors in MM has been hampered by tight therapeutic indices[4, 30] and lack of efficacy
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in early phase studies. Novel agents with broader CDK inhibition[21, 24] and wider
therapeutic indices relative to flavopiridol are needed with compounds such as SCH-72765
and TG-02 in phase 3 and 1 clinical trials, targeted towards patients most likely to respond
with p16 or p18 deletions.
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Figure 1. Myeloma clinical response
At baseline and on day 1 of each subsequent cycle, myeloma clinical labs were repeated and
response determined as determined by the International Myeloma Working Group Criteria
(IMWG). Patient G had serum free light chain disease only. Patients C, F, G, M, N, O, P had
only baseline laboratories drawn – patients F, O, P were replaced during cycle 1 and the
remainder had non-measurable disease per IMWG criteria.
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Figure 2. Plasma flavopiridol concentration versus time
Flavopiridol plasma concentration versus post-infusion initiation time semi-log plots for
patients with evaluable PK profiles. A. Consists of Cycle 1 Day 1 PK profiles (14) from all
dose levels; B. Consists of cycle 1 day 22 PK profiles (7) from all dose levels.
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Figure 3. Comparison of AUC by dose level
A. Relationship between C1D1 AUC0-∞ and dose levels (p=0.024, ANOVA). B.
Relationship between C1D1 Cmax and dose levels (p=0.16, ANOVA). Abbreviations: DL1,
Dose level 1= 30/30 mg; DL2, dose level 2=30/50 mg; and DL3, dose level 3=50/50 mg.
Solid line within the box represents the median, the lower and upper box borders represent
the first and third quartiles, and the whiskers extend to the minimum and maximum values.
The mean is marked with a dotted line. *p<0.05
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Table 2
Toxicities
Toxicity Grade (n)
Adverse Events 2 3 4
Cytopenias
   Neutropenia 1 11
   Anemia 2 7
   Thrombocytopenia 3 2 3
   Lymphopenia 5
Gastrointestinal
   ALT/AST 3 4 3
   Dehydration 2
   Diarrhea 5 6
   Nausea 3
   Vomiting 1
Constitutional
   Fatigue 2 3
   Dizziness 1
   Diaphoresis 1
Electrolyte
   Hyperglycemia 4
   Hyperkalemia 2
   Hypocalcemia 3
   Hypophosphatemia 2 1
Infection
   Neutropenic pneumonia 2
   Neutropenic fever 1
32 22 29
Adverse events (grades 2–4) with an attribution of possible, probable, or definitely related to flavopiridol therapy with the highest grade of all
toxicities per patient tabulated above. Leukopenia was ignored in favor of more specific toxicities of lymphopenia and/or neutropenia. Toxicites
were graded according to CTCAE version 3.0. Small cohort sizes prevented a comparison of toxicities between cohorts.
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Table 3
Plasma cell pretreatment staining
ID Best response BCL-1 RB pRB
H MR 0 2+ 3+
B SD 3+ 1+ 1+ (cytoplasmic)
E SD 3+ 3+ 3+
R SD 0 3+ 3+ (nuclear)
J SD 1+ 2+ 3+ (cytoplasmic)
D SD 0 3+ 2+
K PD 0 3+ 3+
A PD 0 3+ 2+ (cytoplasmic)
Q PD 1 3+ 3+ (cytoplasmic)
C -- 0 3+ 3+ (nuclear and cytoplasmic)
F -- 1+ 3+ 2+
G -- 1+ 2+ 0 (cytoplasm low)
M -- 0 2+ 0
O -- 0 3+ 3+
Immunohistochemistry on paraffin-embedded bone marrow core tissue was performed for BCL-1, retinoblastoma (RB), and phospho-RB (pRB)
and patient IDs were sorted from best response to worst response when possible. A score was assigned which represents the intensity for the
majority of stained plasma cells. 0–1+ will be considered as negative, 2+ as moderate, and 3+ will be strong. The majority of the pRB stains are in
agreement with RB, but patients G and M were not. Patient’s I, L, and P had inadequate plasma cells for staining and are not listed. Best response
per IMWG was listed whenever possible.
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